We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
-13.27%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$18.6B
AUM Growth
-$3.22B
Cap. Flow
-$14.7M
Cap. Flow %
-0.08%
Top 10 Hldgs %
18.18%
Holding
3,301
New
145
Increased
1,425
Reduced
1,371
Closed
260

Sector Composition

Rank Sector Weight
1 Technology 9.03%
2 Financials 4.72%
3 Healthcare 4.25%
4 Consumer Discretionary 4.16%
5 Industrials 2.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RAVE icon
3001
RAVE Restaurant Group
RAVE
$44.2M
$17K ﹤0.01%
15,499
HIL
3002
DELISTED
Hill International, Inc. Common Stock
HIL
$17K ﹤0.01%
10,000
SHCR
3003
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
$16K ﹤0.01%
10,220
-150
-1% -$368
VHC icon
3004
VirnetX Holding Corp
VHC
$64.8M
$15K ﹤0.01%
641
XELA
3005
DELISTED
Exela Technologies, Inc. Common Stock
XELA
$15K ﹤0.01%
33
+14
+74% +$15.2K
NGD
3006
DELISTED
New Gold Inc
NGD
$14K ﹤0.01%
13,019
CFMS
3007
DELISTED
Conformis, Inc. Common Stock
CFMS
$13K ﹤0.01%
1,524
SIEN
3008
DELISTED
Sientra, Inc.
SIEN
$12K ﹤0.01%
1,489
GMBL
3009
DELISTED
Esports Entertainment Group Inc. Common Stock
GMBL
$12K ﹤0.01%
+1
New +$20.7K
BIOR
3010
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$11K ﹤0.01%
60
NAK
3011
Northern Dynasty Minerals
NAK
$930M
$10K ﹤0.01%
38,100
+5,000
+15% +$1.64K
HYRE
3012
DELISTED
HyreCar Inc. Common Stock
HYRE
$10K ﹤0.01%
17,064
+884
+5% +$1.13K
ENDP
3013
DELISTED
Endo International plc
ENDP
$10K ﹤0.01%
20,880
ANY icon
3014
Sphere 3D
ANY
$18M
$9K ﹤0.01%
229
-19
-8% -$1.64K
SMTS
3015
DELISTED
Sierra Metals Inc. Common Stock
SMTS
$9K ﹤0.01%
11,621
FEED
3016
ENvue Medical Inc
FEED
$3.54M
$8K ﹤0.01%
6
ASXC
3017
DELISTED
Asensus Surgical, Inc.
ASXC
$8K ﹤0.01%
20,971
CNSP icon
3018
CNS Pharmaceuticals
CNSP
$7.53M
0
LOTZ
3019
DELISTED
CarLotz, Inc. Class A Common Stock
LOTZ
$7K ﹤0.01%
+18,701
New +$13.8K
HELP
3020
Cybin Inc
HELP
$710M
$6K ﹤0.01%
+264
New +$6.4K
PSFE.WS
3021
DELISTED
Paysafe Ltd Warrants
PSFE.WS
$6K ﹤0.01%
22,000
-23,000
-51% -$8.76K
TLPH icon
3022
Talphera
TLPH
$62.8M
$6K ﹤0.01%
1,259
-150
-11% -$698
AXU
3023
DELISTED
Alexco Resource Corp
AXU
$6K ﹤0.01%
15,578
-2,000
-11% -$1.94K
VERO
3024
DELISTED
Venus Concept
VERO
$5K ﹤0.01%
68
NXTP
3025
DELISTED
NextPlay Technologies, Inc. Common Stock
NXTP
$5K ﹤0.01%
750

Similar funds

Cambridge Investment Research Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Cambridge Investment Research Advisors held 3,301 positions worth $18.6B, down 15% from $21.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Cambridge Investment Research Advisors's Q2 2022 filing shows 145 new, 1,425 increased, 1,371 reduced and 260 closed positions. Its largest new stake was Simplify US Equity PLUS Downside Convexity ETF: 863,983 shares worth $22.9M. The largest sale was Invesco QQQ Trust, an estimated $84.3M.

By sector, the portfolio is most concentrated in Technology at 9% of assets, down from 9.9% a quarter earlier, followed by Financials and Healthcare.

  • Cambridge Investment Research Advisors's largest Q2 2022 buy was Simplify US Equity PLUS Downside Convexity ETF: 863,983 shares worth $22.9M.
  • Cambridge Investment Research Advisors added most to State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q2 2022, an estimated $82M increase.
  • Cambridge Investment Research Advisors's biggest Q2 2022 reduction was Invesco QQQ Trust, cutting an estimated $84.3M.
  • Cambridge Investment Research Advisors fully exited State Street SPDR Bloomberg International Treasury Bond ETF in Q2 2022, selling an estimated $18M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 18% of its $18.6B portfolio in Q2 2022.
  • Cambridge Investment Research Advisors opened 145 new positions and closed 260 in Q2 2022.
  • Cambridge Investment Research Advisors's portfolio value fell 15% quarter-over-quarter to $18.6B.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.